Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Pediatric Asthma
NCT02502734Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone in asthma (2 arms), sponsored by GSK. Primary endpoint: Mean Growth Rate in Lower-leg Growth, as Determined by Knemometry at 2 weeks. Started Sep 2015; status: completed.
02
Drugs
fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02502734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502734.